The adjuvant treatment revolution for high-risk melanoma patients

Francesco Spagnolo, Andrea Boutros, Enrica Tanda, Paola Queirolo

Research output: Contribution to journalReview articlepeer-review


The past 5 years have witnessed the results of many practice-changing studies that have dramatically improved the landscape of adjuvant therapy in patients with resected, high-risk melanoma. After a 20-year era of adjuvant interferon, the anti-CTLA-4 and anti-PD-1 immune-checkpoint inhibitors, and MAPK-directed targeted therapy brought a revolution into the adjuvant treatment of melanoma. These results came along with the practice-changing results of two large multicenter studies showing no benefit in terms of overall survival for completion lymph node dissection after positive sentinel node biopsy. In this review, we summarized the current state of the art of the adjuvant treatment of high-risk melanoma, with a view on future perspectives.

Original languageEnglish
JournalSeminars in Cancer Biology
Publication statusAccepted/In press - Jan 1 2019


  • Adjuvant
  • Immunotherapy
  • Melanoma
  • Neoadjuvant
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'The adjuvant treatment revolution for high-risk melanoma patients'. Together they form a unique fingerprint.

Cite this